Systems Bioengineering Lab studies cellular mechanobiology using combination of multi-omics technologies, quantitative microscopy, and tissue engineering methods
Kirk Campbell, MD
Kidney podocytes are the target cells for injury in human glomerular disease, a significant cause of end stage kidney failure
We utilize cell-based assays and rodent models to identify and characterize key mediators of glomerular disease progression.
Steven G. Coca, DO, MS
Using biomarkers to improve risk-stratification for outcomes in acute and chronic kidney disease
Trials have begun for interventions for kidney disease using biomarker-facilitated enrollment of participants and using biomarkers as endpoints in phase 2 trials.
Paolo Cravedi, MD
Effects of erythropoietin
The immunosuppressive effects of erythropoietin and the identification of biomarkers of acute rejection in kidney transplantation and clinical studies on autoimmune glomerular diseases and renal disease progression.
Ilse Daehn, MD
Exploring the complexity of signaling crosstalk between cells in the kidney
Examining molecular mechanisms in the glomerulus that result in kidney disease progression and diabetic nephropathy in order to identify novel glomerular lesion-specific therapeutic targets and biomarkers.
Luca Gusella, PhD
Pathogenetic mechanisms underlying Autosomal Dominant Polycystic Kidney Disease
Focusing on the early events of cystogenesis and the molecular and cellular responses immediately dependent on the dysregulation of PKD1 or PKD2.
Basil Hanss, PhD
Characterization of a nucleic acid transporter
Defining the mechanisms of nucleic acid transport across the plasma membrane to gain an understanding of the mechanism of transport will allow us to develop strategies to circumvent this barrier.
John Cijiang He, MD, PhD
Pathogenesis of diabetic kidney disease
Study the podocyte and glomerular endothelial cell injury and crosstalk at early diabetic kidney disease
Pathogenesis of HIV nephropathy
Using systems biology approach to identify signaling pathways involved in HIV kidney disease and identifying new drugs and drug targets for treatment of kidney disease
Podocyte biology and pathology
Role of retinoic acid as a therapy for glomerular disease with podocyte injury
Validation of HIPK2 as a potential anti-fibrosis drug target
Peter S. Heeger, MD
Transplantation, complement and T cell biology
Translational research group funded through the NIH that evaluates immune and nonimmune surrogate markers as risk assessment tools for allograft injury in kidney, heart, liver, and lung transplant patients.
Mount Sinai is a clinical site for this study investigating the ability of early inhibition of renal allograft inflammation using TNF-alpha inhibitor to impact subsequent outcomes.
Lewis Kaufman, MD
Understanding the pathogenesis of focal and segmental glomerulosclerosis (FSGS)
FSGS is the most common cause of primary nephrotic syndrome and an important cause of end-stage renal disease worldwide.
Kristin Meliambro, MD
KIBRA (KIdney/BRAin protein), which is an upstream member of the Hippo signaling pathway
Madhav Menon, MD
The SHROOM3 gene is shown to be facilitative for canonical TGF-beta signaling, and fibrosis.
We are currently exploring the role of this gene using an inducible knockdown murine model in renal fibrosis and proteinuria models.
Barbara Murphy, MD
Genetic and genomics in risk stratification in organ transplantation
Investigating the use of genetic variability and differential gene expression to determine individual susceptibility to an allograft to acute rejection, fibrosis and hence graft loss.
A systems biology approach to the identification of genetic drivers of fibrosis in the allograft and the potential application to native kidney. Through this mechanism we have identified several novel mediators of fibrosis which are being investigated further in humans and animal models. SHROOM3 is one such gene. An intronic SNP in SHROOM3 increases expression of SHROOM3 and drives fibrosis in human allograft recipients and murine models of CKD.
Girish N Nadkarni, MD, MPH, CPH
Utilize electronic medical record data and banked biospecimens for risk stratification in patients with chronic kidney disease.
James Post, MD
The prevalence and scope of cognitive impairment in advanced chronic kidney disease
The prevalence of dementia among HD patients has been reported in recent studies to be as high as 38% and under recognized.
Mechanism of tenofovir-induced renal injury
Tenofovir is the most commonly used anti-retroviral medication used to treat HIV-infected patients.
Lisa M. Satlin, MD
Defining the mechanisms leading to the acquisition, maintenance and regulation of transepithelial transport
The focus of the Satlin lab is on defining the mechanisms leading to the acquisition, maintenance and regulation of transepithelial transport in the mammalian cortical collecting duct, the nephron segment responsible in the adult for the final renal regulation of total body K and Na) homeostasis.
Jaime Uribarri, MD
Advanced glycoxidation end products as cardiovascular risk factors in renal failure
Serum levels of advanced glycoxidation end products (AGE) are elevated in diabetes, renal failure.
Dr. Weijia Zhang
Integrative data analysis of high throughput genomic data in human complex diseases
1) genomics analysis of chronic allograft rejection to identify diagnosis/prognosis markers or molecular mechanisms , genetic susceptibility for acute rejection and fibrosis post kidney transplant; 2) genomic/epigenomic analysis of HIV associated kidney diseases; 3) genomic aberrations ( copy number change/gene fusion) and expression dysregulation of human cancer and hematological malignancies. 4) genomics/epigenomics and genetic susceptibility of thyroid diseases